Cerenome, Inc. (NASDAQ:CNSY)
| Market Cap | 11.25M-59.6% |
| Revenue (ttm) | 4.20M-21.0% |
| Net Income | -26.09M-37.1% |
| EPS | -4.43+100.0% |
| Shares Out | 6.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 110,930 |
| Open | 1.62 |
| Previous Close | 1.59 |
| Day's Range | 1.56 - 1.71 |
| 52-Week Range | 1.49 - 20.00 |
| Beta | 1.47 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Oct 15, 2026 |
Insiders here have filed 11 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CNSY
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
$CNSY stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CNSY holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CNSY's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CNSY Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CNSY patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CNSY from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CNSY
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $616.17K |
| VXFVanguard Extended Market ETF | $243.21K |
| IWCiShares Micro-Cap ETF | $42.61K |
Estimated from each fund’s disclosed top holdings × AUM
CNSY Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CNSY’s recent data — informational, not investment advice